Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer

Weniger, Maximilian; Moir, John; Damm, Marko; Maggino, Laura; Kordes, Maximilian; Rosendahl, Jonas; Ceyhan, GÜRALP; Schorn, Stephan

doi:10.1016/j.pan.2020.06.012

Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer

Weniger M., Moir J., Damm M., Maggino L., Kordes M., Rosendahl J., ...More

PANCREATOLOGY, vol.20, no.6, pp.1131-1138, 2020 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 20 Issue: 6
Publication Date: 2020
Doi Number: 10.1016/j.pan.2020.06.012
Journal Name: PANCREATOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
Page Numbers: pp.1131-1138
Keywords: FOLFIRINOX, Gemcitabine, Nab-paclitaxel, Neoadjuvant chemotherapy, ADJUVANT CHEMOTHERAPY, OPEN-LABEL, GEMCITABINE, FOLFIRINOX, RESECTION, ADENOCARCINOMA, PHASE-3, DEATHS
Acibadem Mehmet Ali Aydinlar University Affiliated: Yes

Abstract

Background: Neoadjuvant chemotherapy has become a powerful tool to convert borderline resectable (BRPC) and locally advanced pancreatic cancers (LAPC) into a resectable scenario. However, data analyzing the optimal type of therapy are scarce. In the present multicenter retrospective study, we evaluated the influence of FOLFIRINOX (FFX) and gemcitabine (GEM)-based neoadjuvant therapy on patient prognosis.